Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  TFF Pharmaceuticals, Inc.    TFFP

TFF PHARMACEUTICALS, INC.

(TFFP)
  Report
SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector news

TFF PHARMACEUTICALS, INC. : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K)

share with twitter share with LinkedIn share with facebook
share via e-mail
03/26/2020 | 03:23pm EDT

Item 2.02 Results of Operations and Financial Condition.

On March 26, 2020, TFF Pharmaceuticals, Inc. (the "Company") issued a press release announcing its financial results for the fourth quarter and fiscal year ended December 31, 2019. A copy of the press release is attached as Exhibit 99.1 to this Current Report and is incorporated herein by reference.

The information in this Item 2.02, including the press release attached as Exhibit 99.1 hereto, is furnished pursuant to Item 2.02 but shall not be deemed "filed" for any purpose, including for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, nor shall it be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

Item 9.01 Financial Statements and Exhibits



(d) Exhibits  Method Filing



The following exhibit is furnished with this report:

Exhibit 99.1 Press release dated March 26, 2020 Filed Electronically herewith

             regarding the Registrant's financial
             results for its fiscal quarter and year
             ended December 31, 2019

© Edgar Online, source Glimpses

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on TFF PHARMACEUTICALS, INC.
03/27TFF PHARMACEUTICALS : Management's Discussion and Analysis of Financial Conditio..
AQ
03/26TFF PHARMACEUTICALS, INC. : Results of Operations and Financial Condition, Finan..
AQ
03/26TFF PHARMACEUTICALS : Reports Fourth Quarter Results and Full Year 2019 Financia..
BU
03/23TFF PHARMACEUTICALS RESCHEDULES FOUR : 30 pm (edt)
BU
03/19TFF PHARMACEUTICALS : to Hold Fourth Quarter and Full-Year 2019 Financial and Bu..
BU
03/19TFF PHARMACEUTICALS : Announces Phase 1 Clinical Trial Progress for Voriconazole..
BU
03/12TFF PHARMACEUTICALS : Announces Engagement of J.S. Cole & Associates as Strategi..
BU
03/09TFF PHARMACEUTICALS : Announces Engagement of Torreya Partners, LLC as Strategic..
BU
01/31TFF PHARMACEUTICALS, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
01/28TFF PHARMACEUTICALS : Ascend Capital Founder Malcolm Fairbairn Appointed to TFF ..
BU
More news
Financials (USD)
Sales 2020 -
EBIT 2020 -16,0 M
Net income 2020 -15,7 M
Debt 2020 -
Yield 2020 -
P/E ratio 2020 -5,24x
P/E ratio 2021 -4,70x
Capi. / Sales2020 infx
Capi. / Sales2021 infx
Capitalization 84,2 M
Chart TFF PHARMACEUTICALS, INC.
Duration : Period :
TFF Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends TFF PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 1
Average target price 15,00  $
Last Close Price 4,51  $
Spread / Highest target 233%
Spread / Average Target 233%
Spread / Lowest Target 233%
EPS Revisions
Managers
NameTitle
Glenn R. Mattes President, Chief Executive Officer & Director
Aaron G. L. Fletcher Chairman
Kirk Coleman Chief Financial Officer
Brian J. Windsor Director & Chief Scientific Officer
Robert S. Mills Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
TFF PHARMACEUTICALS, INC.-15.70%84
LONZA GROUP14.61%30 981
CELLTRION, INC.0.72%23 150
IQVIA HOLDINGS INC.-22.54%23 076
SEATTLE GENETICS, INC.6.66%21 035
INCYTE CORPORATION-2.53%18 786